Summary
Cardinal Health Inc. (CAH) reported strong revenue growth in fiscal year 2007, reaching $86.9 billion, a 9% increase from the prior year. This growth was primarily driven by its Pharmaceutical Supply Chain Services segment, which accounted for approximately 86% of total segment revenue, and supported by increased volume from both bulk and non-bulk customers, as well as pharmaceutical price appreciation. However, the company experienced a significant decrease in operating earnings, down 26% to $1.4 billion, largely due to substantial "special items" totaling $772 million. These special items were predominantly driven by litigation settlement reserves ($655 million) and in-process research and development expenses related to acquisitions. Despite the decline in operating earnings, net earnings saw a substantial increase of 93% to $1.9 billion, primarily due to a $1.1 billion after-tax gain from the divestiture of its PTS Business. The company also actively returned capital to shareholders through $3.8 billion in share repurchases and increased dividend payments.
Key Highlights
- 1Revenue grew 9% to $86.9 billion in fiscal year 2007, driven by the Pharmaceutical Supply Chain Services segment.
- 2Operating earnings declined 26% to $1.4 billion due to $772 million in "special items," primarily litigation settlement reserves.
- 3Net earnings increased 93% to $1.9 billion, largely attributed to a $1.1 billion after-tax gain from the sale of the PTS Business.
- 4The company repurchased approximately $3.8 billion of its common stock during fiscal year 2007.
- 5Strategic acquisitions were made, including Viasys for approximately $1.5 billion, to enhance product offerings.
- 6The company reorganized its reportable segments into five categories to better align operations with customer needs.
- 7Despite increased customer discounts impacting gross margins, the company expects to mitigate these pressures through sales growth, cost controls, and synergies from acquisitions.